Ticker

MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July…

Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market opened on Wednesday after Citigroup raised their price target on the stock from $135.00 to $160.00. The stock had previously closed at $110.17, but opened at $118.75. Citigroup currently has a buy rating on the stock. Veradermics shares last traded at

Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss.

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript